All In Biotech

Drug Trial Radar · NCT01626573

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Mar 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Mar 2012

Primary completion

Jul 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Jun 22, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of itacitinib.

Conditions

  • Rheumatoid Arthritis

Interventions

  • ItacitinibDrug

  • Itacitinib PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of itacitinib as assessed by the changes in frequency and severity of adverse events, ECGs, vital signs, physical examinations, and clinical laboratory evaluations.Time frame: Approximately four months.
  2. Preliminary efficacy as assessed by the percentage of patients achieving ACR20 improvement from baseline on the day 28 and day 84 visits.Time frame: Approximately 84 days.

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Palm Desert, California

  • Site not named

    Pasadena, California

  • Site not named

    Lake Mary, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Palm Harbor, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tavares, Florida

  • Site not named

    Lexington, Kentucky

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Lansing, Michigan

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Middleburg Heights, Ohio

  • Site not named

    Duncansville, Pennsylvania

  • Site not named

    Florence, South Carolina

  • Site not named

    Austin, Texas

  • Site not named

    Katy, Texas

  • Site not named

    Spokane, Washington

  • Site not named

    Carolina, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.